Silvester Krčméry, Rastislav Tahotný, Klára Soláriková, Zuzana Gábrišová-Straková
Arterial hypertension occurs in patients with chronic disease of kidneys more and more often. Some groups of antihypertensive drugs are according to the classification K-DOQI preferred in patients with nephropathy. Optimal combinations of medicaments substantially participate in organs’ protection. Several clinical studies suggest that a combined therapy ACEI and sartans can be more effective than monotherapy in reduction of proteinuria and slowing of renal insufficiency progression. In the light of current knowledge candidates for the treatment with this combination are only some groups of patients with chronic nephropathy (patients with proteinuria > 1 g/24 hours, with quickly progressing decrease of glomerular filtration within the activity of chronic glomerulonephritis, diabetic nephropathy, and so on). Potential risks of ACEI combination and sartans are mainly deterioration of renal anaemia and hyperkaliemia.